Wire
Cantor Fitzgerald Adjusts Cigna Price Target to $340 From $325
Cigna Group (CI) has an average rating of Buy and mean price target of $340.96, according to analysts polled by FactSet.Price: $284.21, Change: $-6.37, Percent Change: -2.19%
$CI
$CI
25 stories mentioning CIUpdated 14d ago
Every FINWIRES story that references CI, newest first.
What are analysts saying about CI?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
What's the latest news on CI?
Wire
Wells Fargo Adjusts Cigna Price Target to $305 From $300
Cigna Group (CI) has an average rating of Buy and mean price target of $340.96, according to analysts polled by FactSet.Price: $284.21, Change: $-6.37, Percent Change: -2.19%
$CI
Wire
RBC Capital Adjusts Cigna Price Target to $337 From $333, Maintains Outperform Rating
Cigna (CI) has an average rating of Buy and mean price target of $340.96, according to analysts polled by FactSet.Price: $284.55, Change: $-6.03, Percent Change: -2.08%
$CI
Research
Research Alert: CFRA Maintains Buy Rating On Shares Of The Cigna Group
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target to $330 from $320, based on a 10.9x multiple of our 2026 EPS estimate, near CI's five-year historical forward average of 11.2x. We think CI's multiple balances pharmaceutical business momentum in CI's Evernorth segment and a timely portfolio shift toward more commercial exposure, offset by near-term challenges around higher medical costs across the managed care space. We raise our 2026 EPS estimate by $0.01 to $30.35 and lower 2027's by $0.09 to $33.42. Following Q1 results that beat consensus views, CI's annual Medical Care Ratio (MCR) guidance was maintained at 83.7% to 84.7% for 2026, suggesting cost discipline within a challenging operating environment for managed care. The company plans to exit the Individual ACA Exchange market by year-end 2026, citing the relatively small exposure relative to other parts of CI's portfolio and challenges with meaningfully scaling operations.
$CI
Research
Research Alert: Cigna: Mcr Improvement Supports Q1 Eps Beat, Guidance Raise
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CI reported Q1 2026 adjusted EPS of $7.79 (+16% Y/Y), beating the $7.61 consensus and prompting a $0.10 raise to annual EPS guidance. Total revenues rose 5% Y/Y to $68.5B, due to Evernorth Health Services' growth of 9% Y/Y to $58.4B, while Cigna Healthcare's revenues fell 21% Y/Y reflecting the Medicare business divestiture. The strong Evernorth performance, including 11% Y/Y growth in Pharmacy Benefit Services due to favorable drug mix and 6% Y/Y growth in Specialty and Care Services, supports the company's strategic pivot toward higher-margin services. Management maintained Medical Care Ratio guidance at 83.7%-84.7% for 2026, demonstrating continued cost discipline amid operational improvements. Operational efficiency improved with its SG&A expense ratio declining 100bps to 5.4%, while Cigna Healthcare pre-tax margins expanded 430bps to 13.2% and the Medical Care Ratio improved to 79.8% from 82.2%, primarily benefiting from the Medicare divestiture.
$CI
Showing 21-25 of 25
